Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Removal Of Ban On Federal Funding For Needle Exchange Programs To Be Debated In Congress
An amendment to the fiscal year 2010 appropriations bill for health, labor and education programs that opposes the lifting of the ban on federal funding for needle exchange programs will come to the House floor for debate today along with four others, CQ Today reports. Rep. Mark Souder (R-Ind.) "will offer an amendment to strip language that would lift the ban on federal funding for needle exchange programs," CQ writes. According to CQ Today, "Conservatives are concerned that eliminating the ban on federal funds for such programs, which are designed to reduce the transmission of HIV and other diseases, would be tantamount to helping fund addicts" drug habits. Democrats say science has shown that such programs, when coupled with comprehensive prevention strategies, can reduce the rate of [HIV] infections and do not promote drug use." House Appropriations Committee Chair David Obey (D-Wis.) "added compromise language in the committee this week that would prohibit funds from going to needle exchange programs within 1,000 feet of facilities that serve children, such as schools and parks," the article states. The House is expected to vote on the amendment and the appropriations bill today (Wolfe, 7/23).
generic viagra online
AstraZeneca Studies Show Relief Of Nighttime Heartburn And Reduction In GERD-Related Sleep Disturbances
Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD. NEXIUM, in a class of drugs called proton pump inhibitors (PPIs), demonstrated efficacy in relieving moderate-to-severe nighttime heartburn and GERD-related sleep disturbances in two randomized, placebo-controlled trials(2). These findings were presented in three separate abstracts at Digestive Disease Week 2009 in Chicago.
News of the day
Micromet Presents Update On Blinatumomab's Response Rate And Duration In A Phase 1 Study In Non-Hodgkin's Lymphoma Patients
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, last week presented an update from an ongoing clinical study of the BiTE(R) antibody blinatumomab (MT103) for non-Hodgkin"s lymphoma (NHL) at the 14th Congress of the European Hematology Association (EHA), held June 4 to 7 in Berlin, Germany. Blinatumomab is a novel therapeutic antibody that activates a patient"s T cells to seek out and destroy cancer cells.
Diagnostics

Designer Of The World's First Hand-Held, Non-Contact Vein Illumination Device Meets Stringent ISO 13485 Safety, Design And Distribution Standards

AccuVein LLC, maker of the AV300, the world"s first hand-held, non-contact vein illumination device, announced that its quality system has received an International Organization for Standardization (ISO) 13485 Certification. This certifies to customers around the globe AccuVein"s commitment to the quality and safety of its medical device design, development, production, installation and delivery procedures. The quality system was further designed to meet U.S. FDA Good Manufacturing Practices (cGMP) requirements. AccuVein has begun shipping the AV300 in the U.S. and recently announced agreements with two large group purchasing organizations. In addition the AV300 is available on the General Services Administration Schedule, bringing the AccuVein AV300 to blood centers, hospitals, and government-affiliated institutions across the nation. "AccuVein launched the AV300 to help healthcare professionals locate hard-to-find veins and is committed to ensuring its products are of the highest quality while meeting healthcare provider and patient needs," said Stephen P. Conlon, President of AccuVein. "Receipt of this approval from BSI, an objective and accredited organization, is a critical step forward in our path to deliver the AV300 to healthcare practitioners around the globe." To achieve this three-year certification, AccuVein had to demonstrate that their quality system conforms to the exacting customer and regulatory standards of the ISO. ISO 13485:2003 is specifically designed for regulatory compliance of medical device companies. It supplements ISO 9001 with additional requirements including process control, design control, retention of records, accountability, traceability, and customer satisfaction. AccuVein achieved this key milestone following a careful assessment of their quality management system by BSI Group, a global provider of management systems assessment, certification and training services, with more than 60,000 certified locations and clients in over 100 countries. AccuVein"s quality system meets ISO standard and U.S. FDA Good Manufacturing Practices requirements. For a copy of AccuVein"s ISO 13485:2003 certificate, please visit http://www.AccuVein.com/quality. AccuVein


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009